Acrivon Therapeutics, Inc.
ACRV
$2.37
-$0.04-1.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -6.62% | 3.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.08% | 4.56% | |||
| Operating Income | 13.08% | -4.56% | |||
| Income Before Tax | 13.20% | -6.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.20% | -6.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.20% | -6.74% | |||
| EBIT | 13.08% | -4.56% | |||
| EBITDA | 13.34% | -4.51% | |||
| EPS Basic | 13.42% | -6.43% | |||
| Normalized Basic EPS | 13.42% | -6.42% | |||
| EPS Diluted | 13.42% | -6.43% | |||
| Normalized Diluted EPS | 13.42% | -6.42% | |||
| Average Basic Shares Outstanding | 0.26% | 0.29% | |||
| Average Diluted Shares Outstanding | 0.26% | 0.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||